Putting The Spotlight On STING & TLR Agonists

Preclinical data has been hugely promising when targeting key signalling components of the innate immune system such as the STING or TLR pathways and in recent months we have seen a huge explosion in investment and development in this field. However, challenges remain in terms of translation, clinical development and optimisation of these innate immune stimulating therapies.

The Innate Immune Stimulating Therapies Summit is dedicated to the safe and effective clinical and commercial translation of STING and TLR therapies. Engage in discussions on how to overcome safety challenges and prevent severe adverse events without compromising on efficacy in the tumor micro-environment.

Never attended a digital summit before? No problem; you can find out more about it here.

What Did You Miss?

Innate Immune Stimulating Therapies Summit 2020 Icon-min

Explore model selection to drive and direct clinical trial development with H3biomedicine

Innate Immune Stimulating Therapies Summit 2020 Icon-min

Improve delivery of innate immune stimulating therapies to overcome efficacy and safety challenges with Mersana and Checkmate Pharmaceuticals

Innate Immune Stimulating Therapies Summit 2020 Icon-min

Optimize TLR therapy to accelerate success in clinical trials with GSK

Innate Immune Stimulating Therapies Summit 2020 Icon-min

Advance anti-tumor treatments through development of combination therapy approaches with Aduro Biotech and UPMC

Innate Immune Stimulating Therapies Summit 2020 Icon-min

Induce anti-tumor immunological memory in both the innate and adaptive immune system to achieve a more consistent immune response with Decoy Biosystems

Who Attended In 2020?

Companies Attending